Clindamycin can be taken with or without food; however, taking it with a small amount of food may reduce the likelihood of nausea or stomach upset.
Watery diarrhoea, especially if frequent or accompanied by abdominal pain or fever, may indicate a Clostridioides difficile infection. Seek medical attention promptly for evaluation and possible treatment.
The duration depends on the infection being treated but commonly ranges from 7 to 10 days. Some deep-tissue or bone infections may require longer therapy as directed by a clinician.
Tablets of different strengths often have distinct imprint codes and sizes. Check the imprint on the tablet and compare it with the pharmacy label to confirm the dosage.
Clindamycin is metabolised in the liver, and occasional elevation of liver enzymes can occur. Routine monitoring is recommended for patients with pre-existing liver disease.
Small amounts of clindamycin are excreted in breast milk. Use should be limited to situations where the benefit to the mother outweighs any potential risk to the infant, and only under professional guidance.
Herbal supplements that affect liver enzymes (e.g., St John’s wort) may alter clindamycin levels. Inform your healthcare provider about all non-prescription products you are taking.
Inappropriate or prolonged use can promote resistance among susceptible bacteria. Use clindamycin only as prescribed and complete the full course to minimise this risk.
Because clindamycin is primarily eliminated via the bile, routine dose adjustment for renal impairment is usually unnecessary. Severe hepatic dysfunction may necessitate changes.
Keep the tablets in their original container, protected from excessive heat and moisture. A portable, insulated bag can help maintain a stable temperature during travel.
Clindamycin is an antibiotic belonging to the lincosamide class. It is available in oral pill form in strengths of 150 mg and 300 mg. In the United Kingdom, clindamycin is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is marketed by several pharmaceutical companies under the same generic name, and may appear with different imprint codes depending on the manufacturer.
Clindamycin inhibits bacterial protein synthesis by binding to the 50 S subunit of the ribosome. This prevents the elongation of peptide chains, halting bacterial growth (bacteriostatic). At higher concentrations, it can be bactericidal against susceptible organisms. The drug is well absorbed from the gastrointestinal tract, reaching peak plasma concentrations within 1-2 hours after an oral dose. It is extensively metabolised in the liver and excreted mainly in the bile, with a half-life of approximately 2-3 hours in healthy adults.
Clindamycin is approved by the MHRA for the treatment of:
These indications reflect clindamycin’s activity against Gram-positive cocci and obligate anaerobes. Use is generally limited to adults; pediatric dosing follows separate guidelines and is not covered here.
Several clinical studies have demonstrated that oral clindamycin can reduce inflammatory acne lesions, particularly when combined with other agents such as benzoyl peroxide. Although not licensed for acne in the UK, dermatologists sometimes prescribe it off-label for moderate-to-severe cases that have not responded to first-line topical therapy.
Disclaimer: Off-label use requires supervision by a qualified healthcare professional and an individualized risk-benefit assessment.
Absolute contraindications
Known hypersensitivity to clindamycin or any lincosamide antibiotic.
History of severe colitis caused by Clostridioides difficile (C. difficile) after prior clindamycin therapy.
Relative contraindications
Pregnancy (category B3 in the UK): use only if clearly needed.
Breast-feeding: small amounts are excreted in milk; risk-benefit should be evaluated.
Significant hepatic impairment: dose adjustment may be required.
Patients with renal impairment generally do not require dose modification because clindamycin is primarily eliminated via the bile.
These effects often resolve without intervention; maintaining adequate hydration can help.
Standard dosing for most adult infections
150 mg orally every 6 hours, or 300 mg orally every 8 hours, depending on infection severity and site.
The prescribed regimen should match the strength of the tablet you have (150 mg or 300 mg).
Special populations
Hepatic impairment: Reduce dose by 25-50 % and extend the dosing interval; monitor liver function.
Elderly: No routine dose reduction is required unless liver disease is present.
Administration instructions
Swallow the tablet whole with a glass of water.
Do not crush or chew extended-release formulations (if any).
Missed dose
Take the missed dose as soon as you remember unless the next scheduled dose is within 2 hours; in that case, skip the missed dose. Do not double the dose.
Overdose
Symptoms may include nausea, vomiting, abdominal pain, and diarrhoea. Seek urgent medical care; supportive treatment is the mainstay, and there is no specific antidote.
Discontinuation
For short courses (≤10 days) abrupt cessation is acceptable. Longer therapy for chronic infections may require gradual tapering to minimise the risk of rebound infection, as directed by a prescriber.
This article provides educational information about clindamycin and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
